博拓生物实控人拟减持 2021上市募9亿当年净利即巅峰

Core Viewpoint - The actual controller of Botao Bio (688767.SH), Yu Xiuping, announced a share reduction plan due to personal funding needs, intending to reduce up to 4,479,999 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Yu Xiuping plans to reduce shares through block trading or centralized bidding, with a maximum of 1,493,333 shares (1% of total shares) via centralized bidding and 2,986,666 shares (2% of total shares) via block trading [1][2]. - The reduction period is set for three months starting from 15 trading days after the announcement [1][2]. Shareholding Information - As of the announcement date, Yu Xiuping holds 24,953,600 shares, accounting for 16.71% of the total shares [2]. - The shares intended for reduction were acquired before the IPO and through rights distribution [2]. Financial Performance - Botao Bio's initial public offering raised a total of 921 million yuan, with a net amount of 829 million yuan after expenses, which were 91.96 million yuan [3]. - The net profits attributable to shareholders from 2021 to 2024 were 834 million yuan, 774 million yuan, 107 million yuan, and 170 million yuan, respectively [3].